The activation of IL-17 signaling pathways may vary across different immune diseases, so genomics and biomarker testing could help predict patients’ responses to IL-17 inhibitors, enabling more personalized treatment approaches (Gu et al., 2009). The gene discussed is IL17A; the disease is immune system disorder.